Homburger advises CSL with respect to its announced public tender offer to acquire Vifor Pharma

On December 14, 2021, CSL Limited, a global biotechnology company based in Australia (ASX: CSL), and Vifor Pharma AG, a Swiss-based global pharmaceutical company, announced that they had entered into an agreement for CSL to launch an all-cash public tender offer to acquire all publicly held shares in Vifor for USD 179.25 per share, for an aggregate equity value for Vifor of USD 11.7 bn. Vifor’s board of directors unanimously recommends the offer. Vifor’s largest shareholder, Patinex AG, holding 23,2%, has agreed to tender its shares into the offer.

Homburger AG is advising CSL Limited on the transaction. The Homburger team is led by partners Dieter Gericke and Daniel Häusermann (Corporate / M&A) and comprises counsel Micha Fankhauser (Corporate / M&A), partners Reto Heuberger and Stefan Oesterhelt (both Tax), Benjamin Leisinger (Financing and Investment Products), Richard Stäuber (Competition, Regulatory), Andri Hess and Luca Dal Molin (both IP / IT), associates Olivier Bühlmann, Francesco Bernasconi and Estelle Piccard (all Corporate / M&A), David Thomann (Competition, Regulatory), Sandrine Chabbey (Financing and Investment Products), Marco Bächtold (Employment & Executive Compensation), Philippe Gobet (Tax), as well as junior associates Adrian Bühlmann, Cédric Berger, Tanja Niederer, Joel Schmidt and Lars Schöni.